Tweaking synonymous sites for gene therapy and vaccines
Professor Laurence D Hurst explains why understanding the nucleotide mutations in viruses, including SARS-CoV-2, can have significant implications for vaccine design.
List view / Grid view
Professor Laurence D Hurst explains why understanding the nucleotide mutations in viruses, including SARS-CoV-2, can have significant implications for vaccine design.
Researchers have said that more COVID-19 studies should focus on the mucous membranes of the nose and mouth, to reveal insights into SARS-CoV-2 immunity.
Having analysed the SARS-CoV-2 genomes from over 46,723 patients, researchers have found no mutations that increase transmissibility.
A research team has shown that T-cell responses specific to SARS-CoV-2 remain in the body after infection, providing immunity from mild re-infection.
COVID-19 is known to infect the lungs; however, the dynamics of viral infection and replication are poorly understood. Alongside the Liverpool School of Tropical Medicine, Professor Lyle Armstrong and colleagues have been working to develop a human lung epithelium model of SARS-CoV-2 infection and replication. In this article, he describes…
Researchers from Massachusetts General Hospital have studied several thousand circulating proteins within the plasma proteome of symptomatic COVID-19 patients and acutely ill non-COVID-19 controls. Nikki Withers discussed their findings and implications of the study with one of the lead authors, Dr Mike Filbin.
This in-depth focus features articles on neuropilin-1, a potential new target for COVID-19 drug development, the creation of a lung model to enhance our understanding of SARS-CoV-2 infections and using proteomics to uncover the mechanisms behind COVID-19 symptom severity.
Researchers reveal how two genetic variations may contribute to COVID-19 disease severity and suggest the product of one, the CD209 antigen, may be a potential drug target.
A model of a human lung cell has been used to understand how SARS-CoV-2 uses host cell processes to reproduce, revealing drug targets.
Scientists have shown how SARS-CoV-2 induces changes in the architecture of host cells to drive replication and made their data available to all.
A study in healthcare workers has shown that antibodies from COVID-19 infection protect individuals from reinfection for at least six months.
Using atomistic simulations, a team has demonstrated how coronavirus Spike proteins move and vibrate to let the virus through cell walls.
Scientists developed a new culture technique for alveolospheres which they used to study how alveolar cells respond to SARS-CoV-2 infection.
UKRI will provide £4 million in funding to establish a data infrastructure for scientists in the UK to study antibodies from COVID-19 patient samples.
The non-human primate model exhibited a COVID-19-like disease and showed how symptoms and viral activity change over the course of SARS-CoV-2 infection.